vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and SIMMONS FIRST NATIONAL CORP (SFNC). Click either name above to swap in a different company.
SIMMONS FIRST NATIONAL CORP is the larger business by last-quarter revenue ($197.3M vs $180.9M, roughly 1.1× AVANOS MEDICAL, INC.). On growth, SIMMONS FIRST NATIONAL CORP posted the faster year-over-year revenue change (19.6% vs 0.7%). SIMMONS FIRST NATIONAL CORP produced more free cash flow last quarter ($411.4M vs $21.3M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs 0.6%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Simmons Bank is a bank with operations in Arkansas, Kansas, Missouri, Oklahoma, Tennessee, and Texas. It is the primary subsidiary of Simmons First National Corporation, a bank holding company.
AVNS vs SFNC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $197.3M |
| Net Profit | $-1.3M | — |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | — |
| Net Margin | -0.7% | — |
| Revenue YoY | 0.7% | 19.6% |
| Net Profit YoY | 99.7% | — |
| EPS (diluted) | $-0.02 | $0.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $197.3M | ||
| Q3 25 | $177.8M | $186.7M | ||
| Q2 25 | $175.0M | $214.2M | ||
| Q1 25 | $167.5M | $209.6M | ||
| Q4 24 | $179.6M | $208.5M | ||
| Q3 24 | $170.4M | $174.8M | ||
| Q2 24 | $171.7M | $197.2M | ||
| Q1 24 | $166.1M | $195.1M |
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $-1.4M | $-562.8M | ||
| Q2 25 | $-76.8M | $54.8M | ||
| Q1 25 | $6.6M | $32.4M | ||
| Q4 24 | $-397.3M | — | ||
| Q3 24 | $4.3M | $24.7M | ||
| Q2 24 | $1.8M | $40.8M | ||
| Q1 24 | $-900.0K | $38.9M |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | -42.6% | — | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | -233.0% | — | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | 2.4% | — |
| Q4 25 | -0.7% | — | ||
| Q3 25 | -0.8% | -301.5% | ||
| Q2 25 | -43.9% | 25.6% | ||
| Q1 25 | 3.9% | 15.5% | ||
| Q4 24 | -221.2% | — | ||
| Q3 24 | 2.5% | 14.1% | ||
| Q2 24 | 1.0% | 20.7% | ||
| Q1 24 | -0.5% | 19.9% |
| Q4 25 | $-0.02 | $0.36 | ||
| Q3 25 | $-0.03 | $-4.00 | ||
| Q2 25 | $-1.66 | $0.43 | ||
| Q1 25 | $0.14 | $0.26 | ||
| Q4 24 | $-8.64 | $0.38 | ||
| Q3 24 | $0.09 | $0.20 | ||
| Q2 24 | $0.04 | $0.32 | ||
| Q1 24 | $-0.02 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | — |
| Total DebtLower is stronger | $90.3M | $620.0M |
| Stockholders' EquityBook value | $778.2M | $3.4B |
| Total Assets | $1.1B | $24.5B |
| Debt / EquityLower = less leverage | 0.12× | 0.18× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | — | ||
| Q3 25 | $70.5M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $97.0M | — | ||
| Q4 24 | $107.7M | — | ||
| Q3 24 | $89.0M | — | ||
| Q2 24 | $92.2M | — | ||
| Q1 24 | $75.8M | — |
| Q4 25 | $90.3M | $620.0M | ||
| Q3 25 | $93.4M | $667.8M | ||
| Q2 25 | $95.7M | $1.0B | ||
| Q1 25 | $98.0M | $1.3B | ||
| Q4 24 | $125.3M | $1.1B | ||
| Q3 24 | $152.6M | $1.4B | ||
| Q2 24 | $164.9M | $1.7B | ||
| Q1 24 | $167.2M | $1.2B |
| Q4 25 | $778.2M | $3.4B | ||
| Q3 25 | $778.0M | $3.4B | ||
| Q2 25 | $776.3M | $3.5B | ||
| Q1 25 | $839.4M | $3.5B | ||
| Q4 24 | $828.5M | $3.5B | ||
| Q3 24 | $1.2B | $3.5B | ||
| Q2 24 | $1.2B | $3.5B | ||
| Q1 24 | $1.2B | $3.4B |
| Q4 25 | $1.1B | $24.5B | ||
| Q3 25 | $1.1B | $24.2B | ||
| Q2 25 | $1.0B | $26.7B | ||
| Q1 25 | $1.1B | $26.8B | ||
| Q4 24 | $1.2B | $26.9B | ||
| Q3 24 | $1.7B | $27.3B | ||
| Q2 24 | $1.7B | $27.4B | ||
| Q1 24 | $1.7B | $27.4B |
| Q4 25 | 0.12× | 0.18× | ||
| Q3 25 | 0.12× | 0.20× | ||
| Q2 25 | 0.12× | 0.28× | ||
| Q1 25 | 0.12× | 0.35× | ||
| Q4 24 | 0.15× | 0.32× | ||
| Q3 24 | 0.12× | 0.40× | ||
| Q2 24 | 0.13× | 0.50× | ||
| Q1 24 | 0.14× | 0.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $449.5M |
| Free Cash FlowOCF − Capex | $21.3M | $411.4M |
| FCF MarginFCF / Revenue | 11.8% | 208.5% |
| Capex IntensityCapex / Revenue | 3.8% | 19.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $717.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $449.5M | ||
| Q3 25 | $14.0M | $223.4M | ||
| Q2 25 | $6.8M | $77.6M | ||
| Q1 25 | $25.7M | $32.8M | ||
| Q4 24 | $57.9M | $425.9M | ||
| Q3 24 | $23.0M | $199.4M | ||
| Q2 24 | $27.8M | $86.1M | ||
| Q1 24 | $-8.0M | $57.6M |
| Q4 25 | $21.3M | $411.4M | ||
| Q3 25 | $7.0M | $216.7M | ||
| Q2 25 | $-4.2M | $66.3M | ||
| Q1 25 | $19.0M | $22.6M | ||
| Q4 24 | $53.1M | $380.4M | ||
| Q3 24 | $20.0M | $187.7M | ||
| Q2 24 | $21.9M | $72.7M | ||
| Q1 24 | $-12.1M | $47.7M |
| Q4 25 | 11.8% | 208.5% | ||
| Q3 25 | 3.9% | 116.1% | ||
| Q2 25 | -2.4% | 31.0% | ||
| Q1 25 | 11.3% | 10.8% | ||
| Q4 24 | 29.6% | 182.5% | ||
| Q3 24 | 11.7% | 107.4% | ||
| Q2 24 | 12.8% | 36.9% | ||
| Q1 24 | -7.3% | 24.5% |
| Q4 25 | 3.8% | 19.3% | ||
| Q3 25 | 3.9% | 3.6% | ||
| Q2 25 | 6.3% | 5.3% | ||
| Q1 25 | 4.0% | 4.8% | ||
| Q4 24 | 2.7% | 21.8% | ||
| Q3 24 | 1.8% | 6.7% | ||
| Q2 24 | 3.4% | 6.8% | ||
| Q1 24 | 2.5% | 5.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | 3.89× | 1.01× | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | 8.06× | ||
| Q2 24 | 15.44× | 2.11× | ||
| Q1 24 | — | 1.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
SFNC
Segment breakdown not available.
